Expanded access use of TKM-Ebola in patients with confirmed or suspected Ebola virus infections

Trial Profile

Expanded access use of TKM-Ebola in patients with confirmed or suspected Ebola virus infections

Recruiting
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 11 Nov 2014

At a glance

  • Drugs TKM Ebola (Primary)
  • Indications Ebola virus infections
  • Focus Expanded access; Therapeutic Use
  • Sponsors Arbutus Biopharma
  • Most Recent Events

    • 11 Nov 2014 New trial record
    • 21 Oct 2014 To date, several patients have been treated under this protocol and data collected will be provided to the FDA, according to a Tekmira Pharmaceuticals Corporation media release.
    • 22 Sep 2014 The US FDA and Canada Health have authorised Tekmira to provide TKM-Ebola for treatment under expanded access protocols to subjects with confirmed or suspected Ebola virus infections, according to a media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top